Target intelligence / Profile preview

CDGSH iron-sulfur domain-containing protein 3, mitochondrial (CISD3)

Target
CISD3
Molecular classification
Iron-sulfur protein, NEET protein family (CDGSH iron-sulfur domain containing), Electron transport modulator, Soluble mitochondrial matrix protein (not a membrane-bound enzyme or receptor)
01

Overview

CDGSH iron-sulfur domain-containing protein 3 (CISD3) is a monomeric, soluble mitochondrial matrix protein and a member of the NEET (CDGSH iron-sulfur domain) family. It contains two [2Fe-2S] clusters, which it donates to mitochondrial respiratory complex I and possibly complex II, supporting electron transport and redox balance within mitochondria. Unlike its membrane-bound homodimeric counterparts (mitoNEET/CISD1 and NAF-1/CISD2), CISD3 supports iron homeostasis and the regulation of ROS, influences mitochondrial fission/fusion pathways, and is essential for muscle and overall cellular health. CISD3 is implicated in cancer, diabetes, and neurodegenerative disease through its role in ferroptosis and apoptosis regulation. Its expression serves as a biomarker in several cancers and may be explored as a therapeutic target to induce selective cell death in tumor cells.

Other names
CISD3MiNT (Mitochondrial inner NEET protein)Miner2MitoNEET-related protein 2MitoNEET related 2Mitochondrial inner NEET protein
02

Mechanism of action

Iron chelators promote loss of the iron-sulfur cluster and destabilize CISD3, affecting its role in iron homeostasis and mitochondrial function. Modulation (inhibition or overexpression) of CISD3 impacts mitochondrial iron levels, ROS generation, and ferroptosis—thus, drugs that inhibit CISD3 could promote ferroptotic cell death in cancer therapy.

03

Biological functions

Regulation of iron and redox homeostasis in mitochondriaElectron transport and oxidative phosphorylation supportSupport of complex I and II biogenesis/functionTransfer of [2Fe-2S] clusters within mitochondria and to the cytosolRegulation of mitochondrial morphology and fission/fusionInhibition of ferroptosis (regulated cell death by lipid peroxidation)Regulation of apoptosisMaintenance of muscle tissue and mitochondrial integrity
04

Disease associations

Cancer (tumor growth, ferroptosis, prognosis)Neurodegenerative diseasesDiabetesMuscle degeneration syndromes (such as Duchenne muscular dystrophy)Aging (muscle decline)
05

Safety considerations

Therapeutic targeting of CISD3 could unintentionally cause iron overload, ROS accumulation, and muscle or mitochondrial damage, as CISD3 knockout leads to muscle atrophy, mitochondrial dysfunction, and enhanced ferroptosis/apoptosis.Off-target effects on muscle and nervous tissue due to its ubiquitous role in mitochondrial health.
06

Interacting drugs

No specific drugs directly targeting CISD3 are established or FDA-approved.

1 more in the full profile.

07

Biomarkers

CISD3 expression level is a prognostic biomarker in pan-cancer contexts; low expression predicts poor outcome, and high expression correlates with better prognosis.Its abundance in muscle and cancer tissue may serve as a marker for mitochondrial function and disease progression.

Beyond the preview

Go deeper on CDGSH iron-sulfur domain-containing protein 3, mitochondrial (CISD3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDGSH iron-sulfur domain-containing protein 3, mitochondrial (CISD3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call